We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00322543
First Posted: May 8, 2006
Last Update Posted: October 17, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Conor Medsystems
  Purpose
Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™ pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo lesions of the native coronary arteries.

Condition Intervention Phase
Coronary Disease Device: Corio™ Pimecrolimus-eluting stent Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries

Resource links provided by NLM:


Further study details as provided by Conor Medsystems:

Primary Outcome Measures:
  • Angiographic endpoint of in-stent late lumen loss at 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Major Adverse Cardiac Events (MACE) defined as an adjudicated composite of clinically driven target vessel revascularization, new myocardial infarction (MI) or cardiac death at 30 days, 6 months, 12 months and 2 years; [ Time Frame: 30 days, 6 months, 12 months and 2 years ]
  • Device, Lesion and Procedural Success; Coronary angiography at 6 months; IVUS measurements in IVUS cohort at 6 months. [ Time Frame: 6 months ]

Enrollment: 3
Study Start Date: May 2006
Study Completion Date: May 2008
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug eluting stent
Corio™ Pimecrolimus-eluting stent
Device: Corio™ Pimecrolimus-eluting stent

Detailed Description:
The registry is designed to evaluate 6-month in-stent late lumen loss in patients receiving the Corio™ drug-eluting stent.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

General Inclusion Criteria

  1. Eligible for percutaneous coronary intervention (PCI).
  2. Documented stable or unstable angina pectoris
  3. Left ventricular ejection fraction (LVEF) ≥25%
  4. Acceptable candidate for coronary artery bypass graft surgery (CABG).
  5. Target Lesion < 25 mm in length with RVD of 2.5 to 3.5 mm with visually estimated stenosis of >= 50 and < 100 %.

Exclusion Criteria:

General Exclusion Criteria

  1. Known sensitivity to pimecrolimus, the polymer (PLGA) or cobalt chromium.
  2. Planned treatment with any other PCI device in the target vessel(s).
  3. MI within 72 hours prior to the index procedure
  4. The patient is in cardiogenic shock.
  5. Cerebrovascular Accident (CVA) within the past 6 months.
  6. Acute or chronic renal dysfunction
  7. Contraindication to ASA or to clopidogrel.
  8. Thrombocytopenia
  9. Active gastrointestinal (GI) bleeding within the past 3 months.
  10. Any prior true anaphylactiod reaction to contrast agents
  11. Patient is currently taking chronic systemic steroid therapy or systemic immunosuppressant therapy or topical pimecrolimus.
  12. Female of childbearing potential.
  13. Life expectancy of less than 24 months due to other medical conditions.
  14. Co-morbid condition(s)
  15. Currently participating in another investigational drug or device study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00322543


Locations
Brazil
Institute Dante Pazzanese of Cardiology
Sao Paulo, SP, Brazil, 04012-180
Sponsors and Collaborators
Conor Medsystems
Investigators
Principal Investigator: Alexandre Abizaid, M.D. Institute Dante Pazzanese of Cardiology
  More Information

Responsible Party: Alexandre Abizaid, MD, Institute Dante Pazzanese of Cardiology
ClinicalTrials.gov Identifier: NCT00322543     History of Changes
Other Study ID Numbers: RAPID (Genesis) Registry CP-02
First Submitted: May 4, 2006
First Posted: May 8, 2006
Last Update Posted: October 17, 2008
Last Verified: September 2008

Keywords provided by Conor Medsystems:
Percutaneous coronary intervention (PCI)
Drug eluting stent (DES)

Additional relevant MeSH terms:
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Pimecrolimus
Tacrolimus
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action